Bioinformatics analysis of gene expression alterations conferring drug resistance in tumor samples from melanoma patients with EGFR-activating BRAF mutations

  • Authors:
    • Yang Yu
    • Xueer Wang
    • Qinglin Li
    • Min Zhang
    • Pengcheng Xu
    • Yinghua Chen
    • Yuan Yan
    • Lin Zhang
  • View Affiliations

  • Published online on: November 2, 2017     https://doi.org/10.3892/ol.2017.7330
  • Pages:635-641
Metrics: HTML 0 views | PDF 0 views
0

Abstract

Melanoma is a highly malignant tumor of the skin melanocytes. Patients with this cancer have a high frequency (~50%) of oncogenic BRAF mutations, particularly BRAF V600E. Treatments for melanoma often target BRAF mutations or involve mitogen‑activated protein kinase kinase/extracellular signal‑regulated kinase inhibitors. A major challenge in melanoma treatment is resistance to BRAF inhibitor treatment, which may be enhanced by the BRAF mutation itself and/or epidermal growth factor receptor (EGFR) activation, leading to poor prognosis. However, no effective clinical treatment exists for patients with EGFR‑activating feedback. The aim of the present study was to analyze gene expression changes in tumors from patients with EGFR‑activating BRAF mutations during development of drug resistance. RNA‑seq data was downloaded from the Gene Expression Omnibus (GEO) database for pre‑ and post‑treatment tumor samples from three melanoma patients with EGFR‑activating BRAF V600E mutations, and from The Cancer Genome Atlas (TCGA) melanoma database for tumor and non‑tumor samples from patients with the BRAF V600E mutation and unknown EGFR activation status. Using functional enrichment and KEGG pathway analyses, the present study analyzed differentially expressed genes (DEGs) between pre‑ vs. post‑treatment data from the GEO database and tumor or non‑tumor sample data from the TCGA database. The results of the present study indicated that functional and structural changes to the plasma membrane may be associated with drug resistance. The present study identified 9 DEGs that were significantly different between tumor and non‑tumor samples and also between prior to and following treatment. Thus, it was confirmed that patients with EGFR‑activating BRAF V600E mutations undergo gene expression changes during disease development, and during therapy. These findings may provide potential directions for melanoma‑specific therapy.

Related Articles

Journal Cover

January 2018
Volume 15 Issue 1

Print ISSN: 1792-1074
Online ISSN:1792-1082

2016 Impact Factor: 1.39
Ranked #68/217 Oncology
(total number of cites)

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Yu, Y., Wang, X., Li, Q., Zhang, M., Xu, P., Chen, Y. ... Zhang, L. (2018). Bioinformatics analysis of gene expression alterations conferring drug resistance in tumor samples from melanoma patients with EGFR-activating BRAF mutations. Oncology Letters, 15, 635-641. https://doi.org/10.3892/ol.2017.7330
MLA
Yu, Y., Wang, X., Li, Q., Zhang, M., Xu, P., Chen, Y., Yan, Y., Zhang, L."Bioinformatics analysis of gene expression alterations conferring drug resistance in tumor samples from melanoma patients with EGFR-activating BRAF mutations". Oncology Letters 15.1 (2018): 635-641.
Chicago
Yu, Y., Wang, X., Li, Q., Zhang, M., Xu, P., Chen, Y., Yan, Y., Zhang, L."Bioinformatics analysis of gene expression alterations conferring drug resistance in tumor samples from melanoma patients with EGFR-activating BRAF mutations". Oncology Letters 15, no. 1 (2018): 635-641. https://doi.org/10.3892/ol.2017.7330